scholarly journals Editorial: risk of loss of response to anti TNFα in patients with inflammatory bowel diseases – the longer the less? Authors' reply

2021 ◽  
Vol 55 (2) ◽  
pp. 246-246
Author(s):  
Johannes P. D. Schultheiss ◽  
Remi Mahmoud ◽  
Herma H. Fidder ◽  
Bas Oldenburg
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Loss Of Response ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Sa1257 Persistence of Antibodies to Infliximab for More Than Two Months Predicts Loss of Response to Infliximab in Inflammatory Bowel Diseases

2014 ◽  
Vol 146 (5) ◽  
pp. S-245
Author(s):  
Manon Leclerc ◽  
Hubert Marotte ◽  
Stephane Paul ◽  
Emilie Del Tedesco ◽  
Jean Marc Phelip ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Loss Of Response ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals Vedolizumab in the treatment of inflammatory bowel diseases: whom and how?

2018 ◽  
pp. 44-49
Author(s):  
A. O. Golovenko ◽  
O. V. Golovenko
Keyword(s):  
Ulcerative Colitis ◽  
Clinical Trials ◽  
Clinical Practice ◽  
Inflammatory Bowel Diseases ◽  
Safety Profile ◽  
Actual Clinical Practice ◽  
Loss Of Response ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Available Information

The article is devoted to the use of vedolizumab, an α4β7 integrin antagonist, in the treatment of inflammatory bowel diseases (ulcerative colitis and Crohn’s disease). It presents the results of clinical trials of the drug and the experience of using vedolizumab in actual clinical practice. The latest available information about the drug’s safety profile is provided. The authors considered the practical aspects of therapy, such as determining the indications for treatment, tactics in loss of response, the need for a combination of vedolizumab with immunosuppressors, and the use of the drug in specific categories of patients.

Sign in / Sign up

Export Citation Format

Share Document